Portola May Need Randomized Trial For AndexXa Approval. The Question Is When
Randomized trial represents higher bar for US approval of reversal agents for novel anticoagulants than expected – and if needed prior to approval, could delay AndexXa launch for two or maybe even four years.
You may also be interested in...
Aimovig, Andexxa, Lucemyra, and pegvaliase are among the almost 20 products with upcoming user fee goals at US FDA this month.
In Bristol/Pfizer's ARISTOPHANES real-world study, the rate of major bleeding with Eliquis was 46% lower than J&J/Bayer's Xarelto and 33% lower than Boehringer's Pradaxa.
Bevyxxa finally set to become the fifth new oral anticoagulant on the US market, but in a unique, niche indication of acute medical illness.